PerkinElmer Introduces First Ready-to-use HTRF® and AlphaLISA® Assay Kits for CHO HCP Impurities Detection and Quantification

Rhea-AI Summary

PerkinElmer has launched two innovative no-wash assay kits, HTRF® and AlphaLISA®, aimed at detecting and quantifying CHO HCP impurities in biopharmaceutical manufacturing. These kits enhance efficiency by streamlining workflows and improving sensitivity compared to traditional methods. The assays are designed for high-throughput capabilities with the ability to process samples in 384-well plates, addressing challenges in biomanufacturing. This development supports PerkinElmer's comprehensive solutions for drug development from discovery to quality control.

Positive

• Launch of HTRF and AlphaLISA no-wash assay kits enhances product offering.
• Kits promote a streamlined workflow and higher sensitivity, improving detection of CHO HCP impurities.
• High-throughput capability supports effective quality control in biopharmaceuticals.

Negative

• None.

New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics

WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced two ready-to-use HTRF® and AlphaLISA® no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing. Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities to prevent immunogenicity or reduced potency, stability or overall effectiveness of a drug.

PerkinElmer's HTRF and AlphaLISA CHO HCP kits are the first on the market designed for ready-to-use homogeneous, no-wash assays for the detection and quantification of CHO HCP impurities. These off-the-shelf kits are designed to deliver a streamlined workflow, a broader dynamic range and higher sensitivity than traditional multi-step ELISA assays. The kits are also easily automatable and can be miniaturized to a small sample volume, significantly increasing throughput to 384-well plates.

"The ability to quickly and easily detect, quantify and subsequently eliminate CHO HCP impurities during biopharmaceuticals manufacturing has continued to be a key challenge," said Alan Fletcher, senior vice president life sciences at PerkinElmer. "These innovative HTRF and AlphaLISA assay kits are designed to make this critical step more effective and efficient within existing workflows and contribute to quality control and successful biotherapeutics."

The addition of these assays further propels PerkinElmer’s ability to provide scientists with end-to-end workflow solutions spanning from early stage drug discovery and development with assays, cell lines, microplates and plate readers, into later stage research and development with high-content screening, image analysis and data management, automated liquid handling and more.

Learn more about the new AlphaLISA and HTRF assay kits here and about PerkinElmer’s drug development technologies here.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005527/en/

Media Relations:

Mary Karpa

(215) 896-4022

mary.karpa@perkinelmer.com

Source: PerkinElmer, Inc.

FAQ

What are the new products launched by PerkinElmer?

PerkinElmer has launched two no-wash assay kits: HTRF® and AlphaLISA® for detecting CHO HCP impurities.

How do the new assay kits benefit biopharmaceutical manufacturing?

The new kits streamline workflows, offer higher sensitivity, and allow high-throughput processing in 384-well plates.

What is the significance of detecting CHO HCP impurities?

Detecting CHO HCP impurities is crucial to prevent immunogenicity and ensure the potency and effectiveness of biotherapeutics.

In which industry are these new assay kits used?

These kits are used in the biopharmaceutical industry for quality control during the manufacturing of therapeutic proteins.

What stock symbol is associated with PerkinElmer?

The stock symbol for PerkinElmer is PKI.